FIH to POC: The Journey from Bench to Patient
Quotient Sciences helps clients achieve their FIH and POC milestones, considering that the transition from pre-clinical to clinical testing is a crucial but challenging process.
Progress can be hindered by unpredictable and unknown factors, complicated protocols, and regulatory obstacles that risk delays and endanger investment. Quotient Sciences offers partners the opportunity to benefit from an experienced first-in-human specialist who helps them navigate this stage seamlessly.
Our work with small molecules and biologics allows us to utilise our expertise and resources to progress your novel therapy easily and speedily.
What we do
- Seamlessly integrate early clinical programmes
- This includes SAD/MAD in healthy volunteers and patient cohorts for initial POC, looking at a range of biomarkers. Integrated bioanalysis, PK and data sciences enable rapid turnaround of data and reporting.
- Provide access to special populations and patients for POC assessments
- Access to a broad range of UK- and US-based patient populations in therapeutic areas such as metabolic diseases and CNS diseases, with capabilities for recruitment of special populations, including healthy elderly and post-menopausal women.
- Keep you in control of your programme
- Experienced project management and medical staff, with scientific and regulatory support, keep your clinical study on course, while always keeping volunteer and patient safety in mind.
Key benefits of partnering with us include:
- Decades of Experience: Our experience spans over 35 years and more than 1,300 Phase I studies.
- Enhanced Safety and Oversight: Our experienced clinical teams apply robust protocols and risk-management strategies.
- Operational Excellence: With streamlined processes and cross-functional teams, we deliver predictable timelines and efficient study execution.
- Global Reach, Local Expertise: Programs are led by expert in-house teams including dedicated project managers, skilled scientists, experienced clinical operations, and industry-leading Phase I physicians.
